Molecure S.A. (WSE:MOC)

Poland flag Poland · Delayed Price · Currency is PLN
8.53
-0.45 (-5.01%)
Apr 4, 2025, 10:22 AM CET
-50.81%
Market Cap 151.19M
Revenue (ttm) 1.52M
Net Income (ttm) -30.75M
Shares Out 16.84M
EPS (ttm) -1.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,716
Average Volume 17,082
Open 8.89
Previous Close 8.98
Day's Range 8.53 - 8.89
52-Week Range 8.01 - 17.12
Beta 2.38
RSI 53.98
Earnings Date Mar 28, 2025

About Molecure

Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of c... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 111
Stock Exchange Warsaw Stock Exchange
Ticker Symbol MOC
Full Company Profile

Financial Performance

In 2023, Molecure's revenue was 3.65 million, a decrease of -51.39% compared to the previous year's 7.51 million. Losses were -28.37 million, -21.08% less than in 2022.

Financial Statements

News

There is no news available yet.